Possible explanations for why the positive outcome from this MEK inhibitor study contrasted to the negative result of the MILO/ENGOT-ov11 study23 (the other large randomised MEK inhibitor study in low-grade serous carcinoma) include differences in the number of previous treatment lines or allowed standard-of-care therapies, and in the effectiveness of MEK inhibition. The gene discussed is MAP2K7; the disease is serous adenocarcinoma.